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Abstract
Background: Little is known about the clinical features and true survival risk factors in Chinese Han population. We
conducted the current study to investigate the clinical features, long-term outcome and true potential indicators
associated with mortality of idiopathic inflammatory myopathies (IIM) in China.
Methods: We restrospectvely investigated 188 patients diagnosed with IIM at our hospital from January 1986 to
April 2009. The primary outcome was determined with mortality. The secondary outcomes for survival patients
were organ damage and disease activity, health status, and disability, which were assessed with Myositis Damage
Index, Myositis Disease Activity Assessment Visual Analogue Scales, Health Assessment Questionnaire Disability
Index, and the Modified Rankin Scale, respectively. Potential prognostic factors for mortality were analyzed with the
multivariate Cox regression model.
Results: Mean age at disease onset was 43.8 ± 15.8 years and male to female ratio was 1:2.1 in this cohort. The 1-,
5-, 10-, 15- and 20-year survival rates were 93.6%, 88.7%, 81%, 73.6% and 65.6%. The independent predicators for
mortality were age at disease onset [hazard ratio (HR):1.05, 95% CI 1.02 - 1.08], presence of cancer (HR:3.68, 95%CI
1.39 - 9.74), and elevated IgA level at diagnosis (HR:2.80, 95% CI 1.16-6.74). At the end of the follow-up, 29 patients
manifested drug withdrawal within an average 4.1 years (range 0.5-15.2 year), most patients (85.9%) had no disease
activity and 130 patients (83.4%) had no disability.
Conclusions: The long-term outcomes of IIM patients in our cohort have improved dramatically. Those patients
most likely to survive had a high chance of reaching stable disease status, and obtained long-term or possibly
permanent remission to a large extent.
Background
T h ei d i o p a t h i ci n f l a m m a t o r ym y o p a t h i e s( I I M )a r ea
group of systemic diseases that affect primarily muscle
and skin, but also may affect many other organs, such
as the lungs, heart, joint and gastrointestinal tract [1,2].
They can be classified into polymyositis (PM), dermato-
myositis (DM), juvenile polymyositis or dermatomyositis
(JM), amyophathic dermatomyositis (ADM), overlap
myositis (OM), and inclusion body myositis (IBM) [3-7].
Numbers of survival analyses performed among IIM
patients in Caucasian populations have shown that 5-
year survival ranges from 52%-95% [1,8-14]. Moreover,
previous studies have displayed many predictors of poor
outcome such as old age, male gender, delay in diagno-
sis and therapy, associated malignancy, fever, anti-Jo-1
positive, and the presence of complications (dysphagia,
dysphonia, pulmonary, and cardiac involvement)
[8,9,12-16]. However, there are disagreements among
these studies, especially regarding the role of ethnicity,
clinical manifestation and treatment.
Although it has been suggested that the mortality of
IIM has been greatly reduced, many IIM patients
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any medium, provided the original work is properly cited.continue to exhibit physical disability and organ damage
[1,2,17-21]. However, long-term follow-up studies of
organ damage assessed through standard assessment
tools have been limited. Furthermore, formerly pub-
lished survival data mainly represent mortality and mor-
bidity in non-Chinese Han populations. So far, very
limited data on clinical characteristics, long-term out-
come, and prognostic factors are available for patients
with IIM in the Chinese Han population.
These findings prompted us to assess the clinical char-
acteristics and long-term outcome of Chinese patients
with IIM through using the standard assessment tools;
and to evaluate possible prognostic factors for mortality.
Methods
Patients
We retrospectively reviewed the medical records of 188
patients with IIM excluded inclusion body myositis
which had full clinical information and in our cohort
myositis center (Department of Rheumatology in China-
Japan Friendship Hospital) between January 1986 and
April 2009. The Rheumatology center in the China-
Japan Friendship Hospital is one of the most famous
centers with a particular interest in the disease, and
most patients with IIM referred in our center. There-
fore, our series represent most of the types of IIM
except for juvenile myositis. Because of the Chinese
medical policy, the adult patient hospitals were not per-
mitted to be responsible for the health provision of chil-
dren. The diagnosis of IIM was based on the Bohan and
Peter criteria for PM/DM and Sontheimer’s definitions
for ADM [22,23]. The cases were divided into the fol-
lowing subsets: (i) adult PM and DM; (ii) juvenile PM/
DM (JM) with age < 18 years at diagnosis; (iii) ADM;
(iv) cancer associated with PM/DM; and (v) overlap
myositis (myositis in combination with other connective
tissue disease). Cases which were not Chinese Han
population, or lost to follow-up, or IBM were excluded.
Informed consents were obtained from all patients or
parents. This study was approved by the ethical commit-
tee of the China-Japan Friendship Hospital.
Data collection from clinical charts
Data on history, physical and laboratory findings were
obtained by retrospective medical record review using a
standardized protocol. At the time of visiting to our
center, all patients underwent detailed clinical examina-
tion including extramuscular (interstitial lung disease,
cardiac involvement, dysphagia, pulmonary arterial
hypertension and cancer), laboratory tests (including
autoantibodies), and electromyography (EMG). During
the clinical course of the disease, these tests were
usually conducted as required.
Disease activity at disease onset was assessed by the
Myositis Disease Activity Assessment Visual Analogue
Scales (MYOACT) established by the International
Myositis Assessment and Clinical Studies (IMACS)
Group according to patients’ charts [24].
Definitions for target organ involvement were as fol-
lows: (i) Interstitial lung disease (ILD) was diagnosed if
chest radiograph and high resolution computed temo-
graphy (HRCT) scan indicated the presence of parench-
ymal micronodules and nodules, linear opacities,
irregularity of the interfaces between peripheral pleura
and aerated lung parenchyma, ground-glass opacities,
honeycombing, and traction bronchiectases or bronchio-
lectases, and isolated restrictive pattern on pulmonary
function tests [25]. (ii) cardiac involvement was defined
on the basis of new onset of rhythm disturbances, con-
duction abnormality, cardiomyopathy, myocarditis, or
congestive heart failure during IIM disease course after
ruling out coronary artery disease and other cause of
cardiac diseases such as hypertension, rheumatic heart
disease, congenital heart disease, or diabetes. The diag-
nostic tools for cardiac involvement were detected using
electrocardiography (ECG) or echocardiography, and
biochemistry test including cardiac isoform troponin-I
(cTnI), B type natriuretic peptide (BNP), Creatine
kinases (CK) and CK-MB. (iii) Pulmonary arterial hyper-
tension (PAH) was diagnosed if systolic pulmonary
arterial pressure was greater than 30 mmHg at rest on
doppler echocardiography. (iv) Dysphagia was deter-
mined by dysphagia symptoms, gastroesophageal reflux,
marked decrease of peristalsis or barium persistence
checked by upper gastrointestinal tract visualization.
Follow-up assessment
After the data collection from patient charts, we inter-
viewed each patient by telephone (50/188, 26.6%) or
face to face (138/188, 73.4%) at the outpatient clinic
during May 2010, and collected data of main and sec-
ondary outcomes. Follow-up period was defined from
initial diagnosis to the date of death or to the end of fol-
low-up (May 31, 2010). The main outcome was death
observed; the secondary outcomes for survival patients
were organ damage and disease activity, health status,
and disability, which were assessed with Myositis
Damage Index (MDI) [17,19], MYOACT, Health Assess-
ment Questionnaire Disability Index for adult or child
(HAQDI range 0-3, where 0 indicates no difficulty with
and 3 unable to perform daily activities) [17,18], and the
Modified Rankin Scale (MRS) (score 0: no disability;
score 3: totally dependent) [20], respectively. In addition,
the following clinical assessments were undertaken at
the end of follow-up: treatment status of survival
patients; and causes of death, which were evaluated
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pital, or obtained from family members when the death
occurred outside the hospital.
Assessment of prognostic factors
The following prognostic factors for mortality were ana-
lyzed: age at disease onset; sex; clinical classification of
IIM; disease duration from disease onset to diagnosis;
myalgia, skin ulcers, typical rashes, presence of Ray-
naud’s phenomenon, ILD, cardiac involvement, PAH,
dysphagia, cancer, ANA, anti-Jo-1 and anti-SSA positive
at any time; muscle disease activity and global disease
activity at disease onset; laboratory test results at diag-
nosis including low total protein (TP), low album (ALB),
evaluated IgG, IgA, IgM, Creatine kinase (CK) at initial
visit. There were no missing values among the prognos-
tic factors in the data set.
Disease course assessment
Disease course was defined as monocyclic, polycyclic, or
chronic progress if at least 2 years of follow-up after
diagnosis was available according to the criteria applied
in previous studies [19,20]. Disease course was categor-
ized as not assessed (NA) if there was less than 2 years
of follow-up after diagnosis.
Statistical analysis
Student’s t tests or Mann-Whitney U tests were used for
continuous variables and the c
2 test was performed for
categorical variables. Kaplan-Meier curves were used to
illustrate the proportions of survival and the differences
between groups were tested by using log-rank tests. The
hazard ratios (HR) and 95% confidence intervals (CI) for
death were calculated with Cox proportional-hazards
models. In order to demonstrate possible significant
explanatory risk factors for death, we first analyzed
prognostic factors with the univariate Cox regression
model. Variables with P ≦ 0.15 were considered possible
confounders and retained in subsequent multivariate
Cox proportional hazard analysis. All reported P values
were two-sided. P values less than 0.05 were considered
statistically significant. The statistical package used was
SPSS software version 16.0 (SPSS Inc. Chicago, IL,
USA).
Results
Clinical characteristics of IIM
188 patients were enrolled in the study. Among of them,
158 patients were available for muscle biopsies, while
other 30 patients with dermatomyositis did not did not
undergo muscel biopsies because of classical rash and
muscle presentation. All cases biopsy were confirmed
both by an experienced myopathologist and an experi-
enced rheumatologist with particular interest in the
disease. Clinical characteristics of 188 patients are
shown in Table 1. The 188 patients were classified into
5 groups: DM (53.2%), PM (21.8%), OM (14.4%), ADM
(6.9%), and JM (3.7%). Mean age at onset (± standard
deviation) was 43.8 ± 15.8 years and male to female
ratio was 1:2.1 in all patients. We observed females were
five times more predominant than males in the OM
subgroup, however, males were more predominant than
females in the JM subtype. Among patients with OM,
15 (55.6%) had Sjögren’s syndrome, 11(40.7%) systemic
sclerosis, and 9(33.3%) rheumatoid arthritis, while only 2
(7.4%) had primary biliary cirrhosis.
The lung was the most common extramuscular target in
our cohort patients (Table 1). The overall frequency of
ILD was 48.9%. 16 patients concurred and 76 patients
developed ILD within an average 2.1 years (range: 0.07 to
18 year) after disease onset. All ADM patients in our study
presented with ILD, while JM patients presented with less
ILD (2 out of 11 patients). 20 patients (10.6%) developed
PAH after disease onset. PAH was distributed in OM (n =
7, 35%), DM (n = 7, 35%), PM (n = 6, 30%) patients, but
not found in ADM and JM patients. 64(34%) patients
exhibited cardiac involvement only, with subclinical elec-
trocardiogram (ECG) changes mainly including sinus
tachycardia, ST-T changes, or arrhythmia.
It was noted that 11 patients (5.9%) had malignancies
including three lung cancers, two breast cancers, one
ovarian cancer, one hepatic cancer, one leukemia, one
esophageal carcinoma, one malignant thymoma and one
nasopharyngeal carcinoma. Most of the malignancies
(90.9%) were associated with DM; only one cancer
patient was suffering with PM. The three lung cancers
patients were treated by surgery or chemotherapy with
Carboplatin and VP-16 which were not beneficial for
myositis, patients with breast cancer, esophageal carci-
noma, malignant thymoma, hepatic cancer and naso-
pharyngeal carcinoma were only done surgery, patients
with leukemia were used chemotherapy with Hydroxy-
carbamide which was not beneficial for myositis.
Clinical differences between surviving and non-surviving
patients
Table 2 demonstrates the difference in demographic
characteristics of the surviving and non-surviving groups
during follow-up. There were statistically significant dif-
ferences with regard to mean age at disease onset, pre-
sence of malignancy, cardiac involvement, low TP level
and ALB levels at diagnosis, anti-Jo-1 and anti-SSA
positive (p = 0.000, 0.000, 0.023, 0.044, 0.038, 0.016,
0.048, respectively).
Treatment and Clinical course
The therapies received by patients in our patients were
varied according to disease severity, experience of
Shu et al. BMC Neurology 2011, 11:143
http://www.biomedcentral.com/1471-2377/11/143
Page 3 of 11treating physician and changing treatment strategies. All
patients received corticosteroid at a dose between 0.5
mg/kg and 1 mg/kg as part of their initial therapy after
suspecting a diagnosis of IIM. Meanwhile, because of
the concerns about steroid side-effects, the well
improved response to immunosuppressants with earlier
administration and personalized treatment, over three-
quarters of our patients (145/188, 77.1%) also received
at least one or more of immunosuppressants including
methotrexate (83/145, 57.2%), cyclophosphamide (87/
145, 60%), azathioprine (62/145, 42.8%), intravenous
immunoglobulin (IVIG) (31/145, 21.4%), hydroxychloro-
quine (17/145, 11.7%) or mycophenolate mofetil (18/
145, 12.4%).
In 166 patients with a follow-up time of at least 2
years, the disease course was monocyclic in 25 patients
(15.1%), polycyclic in 132 patients (79.5%) and chronic
progressive in 9 patients (5.4%). We further compared
the difference in disease course in surviving and non-
surviving patients. The results showed the polycyclic
course predominated in surviving patients (p = 0.000),
w h i l et h ec h r o n i cp r o g r e s s i v ec o u r s em a i n l ye x i s t e di n
non-surviving patients (p = 0.017).
Mortality and prognostic factors for death
The mean follow-up time was 7.5 years. Disease-related
deaths occurred in 17% of all patients. The cumulative
survival estimate was 93.6%, 88.7%, 81%, 73.6% and
65.6% for 1, 5, 10, 15, and 20 years, respectively (Figure
1A). Survival analysis for further clinicopathologic sub-
groups revealed that patients with various forms of IIMs
have different survival rates (Figure 1B).
Although death events have been observed at 1-15
years after disease diagnosis, a bimodal overall mortality
distribution of IIM was established; with an initial peak
at around the first 3 years (eighteen of the 32 deaths)
and a second smaller peak occurring in 5-15 years
(twelve of the 32 deaths) after disease diagnosis (Figure
1C). Figure 1D shows a plot of the total number of
patients according to the follow-up time.
To maximize and identify the independent predictors
for mortality, we first analyzed prognostic factors with
the univariate Cox regression model in which variables
with P ≦ 0.15 were considered possible confounders and
retained in subsequent multivariate Cox proportional
hazard analysis. The univariate analysis revealed that age
at disease onset (p < 0.001), skin ulcers (p = 0.01), cardiac
involvement (p = 0.11), presence of cancer (p < 0.001) or
ILD (p = 0.12), low TP level (p = 0.15), low ALB level (p
= 0.02), and elevated IgA at diagnosis (p = 0.08) were
likely to be the risk factors for mortality. Meanwhile, dys-
phagia (p = 0.11), myalgia (p = 0.01) and anti-SSA posi-
t i v ea ta n yt i m e( p=0 . 1 1 )w e r es h o w nt ob ep o s s i b l e
protective factors. Because there could be interactions
among these factors, we further confirm these predica-
tors with multivariate analysis. The independent predic-
tors for mortality were age at disease onset [hazard ratio
(HR):1.05, 95% CI 1.02-1.08], the presence of cancer
(HR:3.68, 95%CI 1.39 - 9.74), and elevated IgA level at
diagnosis (HR:2.80, 95% CI 1.16, 6.74).
Long-term outcomes in surviving patients
156 surviving patients were personally reexamined after
a mean follow-up of 8.1 years (range 1.42-28 years). 115
Table 1 Classification, demographics, clinical characteristics and treatment of patients with idiopathic inflammatory
myopathies
All PM DM ADM OM JM P value
No. of patients no(%) 188 41(21.8) 100(53.2) 13(6.9) 27(14.4) 7(3.7)
Died 32 5 20 4 2 1 NA
Mortality (%) 17.0 11.9 20 30.8 7.69 14.3 NA
Male: female ratio 1:2.1 1:2.4 1:1.8 1:1.6 1:8 1:0.4 NA
Mean age ± S.D at onset (y) 43.8(15.8) 44.9(15.0) 44.9(14.9) 50 (13.8) 42(16.8) 15.7(2) < 0.001†
Complicated with ILD, n, % 92(48.9) 17(40.5) 49(49.0) 13(100.0) 11(42.3) 2(28.6) 0.003
Complicated with PAH, n, % 20(10.6) 7(16.7) 7(7.0) 0(0.0) 6(23.1) 0(0.0) > 0.05
Complicated with malignancy, n, % 11(5.9) 1(2.4) 10(10.0) 0(0.0) 0(0.0) 0(0.0) > 0.05
Complicated with oropharyngeal dysphagia, n, % 75(39.9) 14(33.3) 36(36.0) 5(38.5) 15(57.7) 5(71.4) > 0.05
Cardiac involvement, n, % 64(34.0) 14(33.3) 37(37.0) 4(30.8) 4(15.4) 5(71.4) > 0.05
Mechanic hand at anytime, n, % 28(14.9) 1(2.4) 21(21.0) 3(23.1) 3(11.5) 0(0.0) 0.038
Raynaud phenomenon at anytime, n, % 29(15.4) 5(11.9) 10(10.0) 3(23.1) 11(42.3) 0(0.0) 0.001
Creatine kinase at initial visit in our center, mean (IQR) 1440.9
(83, 1561.8)
2106.8
(594.5, 2577.5)
1117.4
(68.3, 971.3)
67.9
(35, 93.5)
1867.9
(236, 2452)
3065.4
(114, 7908)
0.013††
† indicates that the comparison between PM, DM, ADM, OM, vs JM (p < 0.001), but the comparison among PM, DM, ADM and OM were no significant.
††indicates that the comparison between PM vs DM (p < 0.05), PM vs ADM (p < 0.01), DM vs JM (p < 0.05), ADM vs OM (p < 0.05), ADM vs JM (p < 0.01).
PM: polymyositis; DM: dermatomyositis; ADM: amyopathic dermatomyositis; OM: overlap myositis; JM: juvenile polymyositis or dermatomyositis; ILD: interstitial
lung disease; PAH: pulmonary arterial hypertension; IQR: interquartile range; NA: not assessment.
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occurred most frequently in the pulmonary system, fol-
lowed by the skeletal, endocrine, muscular and cuta-
neous systems (Table 3).
Table 4 shows the physical status, functional ability,
disease activity and drug use status of survival patients
at the end of the follow-up. 85.9% of the patients had
no disease activity, as shown by global disease activity
10-cm VAS score = 0. Only 14.1% of the patients had a
score > 0. Twelve (7.7%) patients exhibited muscle dis-
ease activity that defined with muscle disease activity
10-cm VAS score > 0.2. As measured by the HAQDI,
130 patients had no disability at all, and 26 patients had
mild to moderate disability. Similar results were
obtained by MRS with regard to disability.
29 patients (18.6%) were off all drugs after 4.5 years
(range 0.7-14 years) of treatment, and they had been off
drugs for an average of 4.1 years (range 0.5-15.2 years).
Table 2 Demographic characteristics of survival and non-survival groups during follow-up
Variables Non-survival group Survival group P values
No. of patients (%) 32(17.0) 156(83.0)
Sex, no. (%)
Male: female ratio 01:01.9 01:02.1 0.837
Classification of diagnosis
PM 5(15.6) 37(23.7) 0.363
DM 20(62.5) 80(51.3) 0.331
ADM 4(12.5) 9(5.8) 0.241
OM 2(6.25) 24(15.4) 0.261
JM 1(3.13) 6(3.9) 1
Mean age ± S.D at onset (year) 52.9 ± 15.8 41.9 ± 15.2 0
Disease duration from onset to diagnosis, median (IQR) year 3.8(2, 12.8) 6.5(3, 12) 0.215
Skin ulcers, (%) 6(18.8) 15(9.6) 0.212
Complicated with ILD at disease course, (%) 17(53.1) 75(48.1) 0.558
Complicated with PAH at disease course, (%) 3(9.4) 17(10.9) 1
Complicated with malignancy, (%)e 7(21.9) 4(2.6) 0
Complicated with dysphagia at disease course, (%) 8(25.0) 67(42.9) 0.074
Cardiac involvement at disease course, (%) 17(53.1) 47(30.1) 0.023
Raynaud phenomenon at disease course, (%) 4(12.5) 25(16.0) 0.79
Low TP level† at diagnosis, (%) 10(31.3) 24(2.6) 0.044
Low ALB levels† at diagnosis, (%) 16(50.0) 46(29.5) 0.038
Elevated IgG†† at diagnosis, (%) 8(25) 47(30.1) 0.672
Elevated IgA†† at diagnosis, (%) 9(28.1) 25(15.4) 0.122
Elevated IgM†† at diagnosis, (%) 5(15.6) 20(12.8) 0.775
Creatine kinase at initial visit in our center, median (IQR) 260.5
(71.8, 1173.8)
491.5
(83.3, 1613.5)
0.489
Autoantibodies positive at disease course, (%)
ANA positive 16(50.0) 85(54.5) 0.699
Anti-RNP positive 4(12.5) 13(8.3) 0.497
Anti-Jo-1 positive 0(0.0) 24(15.4) 0.016
Anti-SSA positive 2(6.3) 33(21.2) 0.048
MYOACT global disease activity, 10-cm VAS score at disease onset 6.21 ± 2.61 6.64 ± 2.60 0.408
MYOACT muscle disease activity, 10-cm VAS score at disease onset 7.09 ± 1.34 6.91 ± 1.3 0.47
MYOACT, subscale VAS score > 0 at disease onset
Constitutional 25(78.1) 129(82.7) 0.614
Cutaneous 25(78.1) 111(71.2) 0.518
Skeletal 10(31.3) 42(26.9) 0.666
Gastrointestinal 9(28.1) 57(36.5) 0.421
Pulmonary 4(12.5) 12(7.7) 0.483
Cardiac 9(28.1) 35(22.4) 0.497
†refers to values that are below the lower limit of normal laboratory assay standards.
††refers to values that are higher than the upper limit of normal laboratory assay.
ANA, antinuclear antibody; RNP, ribonucleoprotein; SSA: Sjögren’s syndrome antigen.
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patients (46.8%) were taking corticosteroid with dosage
of ≤5 mg/d, 34 patients (21.8%) were taking corticoster-
oid with dosage of 5 to 10 mg/d, 9 patients (5.8%) were
taking corticosteroid with dosage of 10 to 15 mg/d, 11
patients (7.1%) were taking corticosteroid with dosage of
> 15 mg/d, and 30(19.2%) patients were taking second-
line agents.
Discussion
This study was a mean 7.5 years follow-up of a large,
single centre cohort of patients with IIM classified with
PM, DM, ADM, OM and JM in China. To our knowl-
edge, this is the first study to describe the long-term
organ damage and physical health status in a large
cohort of patients with IIM from China, utilizing stan-
dardized tools such as MDI, HAQDI and MRS. In this
study, we have demonstrated that patients with IIM in
China have good outcomes over long-term follow-up.
Few statistics on age at disease onset have been obtained
directly in previous studies. Most studies reported age at
diagnosis. In this retrospective cohort study, we described
the relative “true” disease age through utilizing age at dis-
ease onset, although many of inflammatory myopathies
have an insidious onset and early course which may lead
difficult to establish a true onset.
Study on risk factors and survival of IIM patients with
ILD has been reported from China. It was reported Chi-
nese IIM patients tended to have high frequency of IIM-
associated ILD [26]. The prevalence of ILD was higher
Figure 1 Kaplan-Meier estimate of survival of 188 Chinese Han population patients with IIM, and stratified according to the type of
myopathy. A. Survival curves of patients with IIM 1 year survival rate is 93.6%, 5 year survival rate is 88.7%, 10 year survival rate is 81.0%, 15 year
survival rate is 73.6%, 20 year survival rate is 65.6%; B. Survival curves stratified according to the subtypes of IIM. C. Death number within entire
follow-up period. The mortality of IIM patients in China was characterized with double hump-like shape. D. shows a plot of the total number of
patients at follow-up time. > 20 indicate the time of follow-up is over 20 years.
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nian patient than Caucasian patients with IIM [27-30].
Indeed, about 50% of Chinese and Japanese patients
with IIM develop ILD whereas only approximate 30% of
Caucasian patients with IIM develop ILD [20,25-31].
High frequency of IIM-associated ILD may be a specific
feature in eastern Asia.
An association between IIM and cancer has been
widely reported in the literature. Several studies from
Japan, European and American indicated that the overall
prevalence of malignancy in IIM ranged from 9% to 40%
[8-10,12,13,15,21,29,32-35]. However, our study showed
very low prevalence of malignancy (5.9%), which is con-
sistent with a study from Arab Jordan [27]. Indeed, our
study was also similar to a recent finding from a nation-
wide cohort study of 1655 Chinese patients with PM/
DM from Taiwan in which 128 patients (7.7%) had
malignancies [36].
In various studies, mortality rates have varied from
10%-40% [1,8-11,13-15,17,18]. However, some of those
previous investigations excluded overlapping, juvenile,
ADM, or malignancy-associated cases, which are impor-
tant subgroups of IIM. This retrospective study of 188
IIM patients is more representative of overall IIM
patients. The overall mortality in our study was 17%,
similar to other published series [11,18,31,37], but lower
than that Troyanov Y reported [7]. Importantly, our
results indicated that cumulative survival rate was better
than other series reported over 15 years (Table 5)
[7,9-12,15,29,32,33]. Our analyses show that high mor-
tality occurred within 3 years, which was consistent with
previous studies (Figure 1C) [8,9]. There was another
death peak within 5 to 15 years in our IIM patients. In
view of two significant peak of mortality within three
years, and 5 to 15 years, we further studied the altera-
tion after excluding patients with a follow-up of less 3
years and 10 years. Results showed that when patients
with a follow-up of less than 3 years were excluded, the
survival rate was 99.3%, 97.7%, 89.2%, 81.1% and 72.3%
Table 3 Frequency of damage in the IIM patients at the
end of the follow-up using the Myositis Damage Index
(MDI)
Damage item Survival IIM patients‡,
n = 156, (%)
Muscle severity, VAS 31(20.0)
Muscle atrophy 7(4.7)
Weakness 53(34.0)
Muscle dysfunction 10(6.7)
Skeletal severity, VAS, no of test(149)
# 44(29.4)
Joint contracture 1(0.7)
Osteopososis with fracture 4(2.8)
Avascular necrosis 5(3.5)
Arthropathy 9(6.3)
Cutaneous severity, VAS 31(20.0)
Calcinosis 7(4.7)
Alopecia 2(1.3)
Cutaneous scarring 15(9.3)
Poikiloderma 20(12.7)
Lipodystrophy 4(2.6)
Gastrointestinal severity, VAS 8(5.3)
Dysphagia 8(5.3)
Gastrointestinal dysmotility 1(0.7)
Gastrointestinal infarction 1(0.7)
Pulmonary severity, VAS 77(49.3)
Dysphonia 11(7.1)
Impaired lung function 75(48.1)
Pulmonary fibrosis 75(48.1)
Pulmonary hypertension 20(12.8)
Cardiovascular severity, VAS 27(17.3)
Hypertension 26(16.7)
Ventricular dysfunction 2(1.3)
Angina 3(1.9)
Myocardial infarction 3(1.9)
Peripheral vascular severity, VAS 2(1.3)
Tissue pulp loss 0(0.0)
Digit loss 2(1.3)
Thrombosis 0(0.0)
Claudication 0(0.0)
Endocrine severity, VAS 41(26.3)
Growth failure 0(0)
Delay in secondary sexual characteristics 0(0)
Hirsutism 0(0.0)
Irregular menses 2(1.3)
Amenorrhea 0(0.0)
Diabetes 41(26.3)
Infertility NA
Sexual dysfunction NA
Ocular severity, VAS 4(2.7)
Cataract 2(1.3)
Vision loss 1(0.6)
Infection severity, VAS 4(2.6)
Chronic infection 3(2.0)
Multiple infections 1(0.6)
Table 3 Frequency of damage in the IIM patients at the
end of the follow-up using the Myositis Damage Index
(MDI) (Continued)
Malignancy severity, VAS 4(2.6)
Malignancy 4(2.6)
Total damage
Total MDI severity of damage > 0† 112(71.8)
Total MDI extent of damage > 0‡ 115(73.7)
#indicates the number after excluded the patients complicated with
rheumatoid arthritis (n = 7) NA: not applicable. VAS, visual analogue scale.
† Severity of damage was assessed in 9 organ systems and 2 categories of
illness (infection and malignancy) and summed to provide a total MDI severity
of damage score.
‡ Individual damage items were assessed in each organ system and category
of illness and summed to provide a total MDI extent of damage score.
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Page 7 of 11in 3, 5, 10, 15, and 20 years. Moreover, the 10-year, 15-
year, and 20-year cumulative survival estimate of
patients with a follow-up of over 10 years (n = 53) was
97.8%, 90.9%, 81%, and 73.6%, respectively. These data
suggested that to improve the long-term outcome, con-
tinue three years of intensive outcome monitoring is
recommended for patients with IIM.
The predictors of mortality varied in different studies.
Our study found presence of cancer and age at disease
onset were associated with higher mortality, in agree-
ment with published work [8-15,20]. Moreover, for the
first time, elevated serum IgA at diagnosis was identified
as an unexpectedly strong prognostic factor associated
with mortality. An explanation for this may be that it
seems to be related indirectly to the severe extent of
muscle damage and might reflect the overall disease
severity of inflammatory process. Several studies indi-
cated that serum IgA antibodies in immune complexes
are very effective at initiating a wide range of inflamma-
tory responses, including phagocytosis, antibody depen-
dent cellular cytotoxicity, oxidative burst, and cytokine
release [38,39]. Inflammatory responses triggered by IgA
are often mediated by the IgA-specific receptor FcaRI.
A number of diseases including autoimmune diseases
such as Sjogren’s syndrome exhibit elevated levels of
serum IgA. In the autoimmune disease Sjögren’ss y n -
drome, characterized by lymphoid cell infiltration of
lacrimal and salivary glands, the N-glycans of mono-
meric IgA1 are oversialylated, which could presumably
affect the FcaRI-IgA interaction and alter recycling of
IgA [40]. The study suggested that elevated IgA in IIM
may also trigger inflammatory responses in a manner
similar to Sjögren’s syndrome, which then resulted in
muscle damage. However, thise x a c tp o t e n t i a lr o l eo f
elevated IgA in the pathogenesis and outcome of inflam-
matory myopathies need other studies to elaborate in
animal model and patient population.
Our study found that skin ulcer was a predictor for
mortality in the univariate analysis (HR 3.17, 95% CI
1.27-7.93, p = 0.01), while it was not an independent
predictor for mortality in the multivariate analysis. This
is not consistent with a recent report from Japan which
indicated that skin ulcer was an independent risk factor
for prognosis [29]. There is still some debate on the
relationship between skin ulcer and outcome. Several
studies showed that skin ulcer was not associated with
the risk of mortality in Chinese Han patients and Cau-
casian patients [8-10,13,15,17,20,33,32,37].
Previous studies from Japanese and Caucasian indi-
cated that ILD was poor risk factor of IIM. Our study
Table 4 Disease status and drug use status of survival patients with IIM through using the MDAAT, HAQDI and MRS at
the end of follow-up.
All PM DM ADM OM JM
No. of patients (%) 156 37 80 9 24 6
MYOACT global disease activity, 10-cm VAS score = 0, n. (%) 134(85.9) 31(83.8) 69(86.3) 7(77.8) 21(87.5) 6(100.0)
MYOACT global disease activity, 10-cm VAS score > 0, n. (%) 22(14.1) 6(16.2) 11(13.8) 2(22.2) 3(12.5) 0(0.0)
MYOACT muscle disease activity, 10-cm VAS score > 0.2, n. (%) 12(7.7) 3(8.1) 6(7.5) 2(22.2) 1(4.2) 0(0.0)
MYOACT, subscale VAS score > 0.2, no (%).
Constitutional 13(8.3) 1(2.7) 9(11.3) 1(11.1) 2(8.3) 0(0.0)
Cutaneous 11(7.1) 1(2.7) 6(7.5) 2(22.2) 2(8.3) 0(0.0)
Skeletal 7(4.5) 4(10.8) 2(2.5) 0(0.0) 1(4.2) 0(0.0)
Gastrointestinal 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Pulmonary 15(9.6) 6(16.2) 6(7.5) 2(22.2) 1(4.2) 0(0.0)
Cardiac 2(1.3) 2(5.4) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Patients with HAQDI score = 0, n. (%) 130(83.3) 33(89.2) 64(80.0) 8(88.9) 17(70.8) 6(100.0)
Patients with HAQDI score > 0, n. (%) 26(16.7) 4(10.8) 15(18.8) 1(11.1) 6(25.0) 0(0.0)
Patients with M RS = 0, n. (%) 131(84.0) 34(91.9) 66(82.5) 9(100) 16(66.7) 6(100.0)
Patients with MRS ≥1, n. (%) 25(16.0) 3(8.1) 14(17.5) 0(0.0) 8(33.3) 0(0.0)
Medication
Off all drugs 29(18.6) 9(24.3) 16(20.0) 1(11.1) 3(12.5) 0(0.0)
Corticosteroid, 0-5 mg/d, n. (%) 73(46.8) 16(43.2) 37(46.3) 4(44.4) 12(50.0) 4(66.7)
Corticosteroid, 5-10 mg/d, n. (%) 34(21.8) 8(21.6) 17(21.3) 2(22.2) 5(20.8) 2(33.3)
Corticosteroid, 10-15 mg/d, n. (%) 9(5.8) 1(2.7) 6(7.5) 0(0.0) 2(8.3) 0(0.0)
Corticosteroid, > 15 mg/d, n. (%) 11(7.1) 3(8.1) 4(5.0) 2(22.2) 2(8.3) 0(0.0)
Second-line agents†, n. (%) 30(19.2) 10(27.0) 14(17.5) 1(11.1) 3(12.5) 2(33.3)
MYOACT, the Myositis Disease Activity Assessment Visual Analogue Scales; VAS, visual analogue scale; HAQDI, health assessment questionnaire disabled index;
MRS, modified rankin scale.
†second-line agents include methotrexate, cyclophosphamide, azathioprine, intravenous immunoglobulin, hydroxychloroquine or mycophenolate mofetil.
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Page 8 of 11failed to identify several risk factors such as ILD, cardiac
involvement, dysphagia that were often reported in pre-
vious studies. This may be explained as follows. First,
there was no difference in the frequency of ILD and
dysphagia found between non-survival and survival
patients (Table 2). Second, we postulated another reason
to be the early detection and aggressive therapy of these
ILD patients. All of our patients with ILD received com-
binational treatment including corticosteroid and cyclo-
phosphamide, azathioprine, IVIG, hydroxychloroquin or
mycophenolate mofetil; and they responded to drugs
well. In fact, there were two studies in Taiwan and
France had found a similar result such that ILD and
heart involvement did not influence the survival of DM/
PM patients [25,28]. Third, dysphagia was improved in
our study patients after diagnosis with treatment, which
in turn helped to improve prognosis. Further, cardiac
involvement in our study involved mainly subclinical
features which may not influence the prognosis.
The disease duration from onset of signs to diagnosis
was much longer than previous studies [9-12], however,
the disease duration in our cohort study did not have
effect on the prognosis, which may be explained in that
some of our patients had already initiated corticosteroid
therapy or immune-suppressed agents according to dis-
ease manifestation before the diagnosis of IIM. Our
study also indicated that PM has better survival than
DM (Figure 1B), which was very different from a
number of other myositis mortality reports
[9,15,29,33,32]. It is possible that the results are con-
founded by the inclusion of cancer-associated myositis
within these clinical subgroups, rather than as a separate
subgroup of patients.
The overall surviving patients in this study have favor-
able long-term outcomes assessed with MDI, MYOACT,
HAQDI and MRS after a mean of 8.1 years of disease
duration. Importantly, our findings suggested that sur-
viving patients had less frequency of organ damage than
in adult patients described by Rider LG et al [19].
Furthermore, it is noteworthy that only a small sizable
proportion of the patients had persistently active disease
at the end of the follow-up, as shown by the 7.7% or
14.1% frequency of abnormal muscle disease activity or
MYOACT global disease activity scale, respectively. Dis-
ease activity was seen much more frequently in the pul-
monary system, followed by constitutional symptoms
such as fatigue, and skin complaints. Although the sam-
ple size of JM (6 survival patients at the end of follow-
up) in this study was small, it is still noteworthy that all
the surviving JM patients presented no active disease.
Ravelli A et al demonstrated that persistently active dis-
ease was recorded in 41.2-60.5% of patients suffering
juvenile dermatomyostis [17]. A similarly high frequency
of persistently active juvenile dermatomyositis at the
time of follow-up was reported in a Canadian multicen-
ter [41]. The physical disability in our study was less
Table 5 Survival of patients with IIM at previous reports and this study
First author, published
year (Ref)
location Follow-up Mean
follow-up
No. of
patients
Clinical-pathologic
subgroup
Survival rates (%)
1-
year
5-
year
> 5-year
Medsger 1971 [10] USA 1947-1968 7 years 124 PM, DM, JDM, OM, CAM 72 65 53(7 yr)
Benbassat1985 [8] Israel 1956-1976 20 years 92 PM, DM, JDM, OM, CAM 72 52 –
Hochberg1986 [11] USA 1970-1981 8 years 76 PM, DM, JDM, OM 94.5 80.4 72.8 (8 yr)
Maugars 1996 [9] France 1973-1998 – 69 PM, DM, JDM, OM, CAM 82.6 66.7 55.4 (9 yr)
Uthman 1996[31] France 1980-1992 5.2 years 30 PM, DM, CAM, OM – 89 85(10 yr)
Marie 2001 [12] France 1983-1999 4 years 77 PM, DM, CAM 83 77 61 (15 y)
Sultan 2002 [1] England 1978-1999 20 years 46 PM, DM, JDM, OM 95 83.8 (10 yr)
Dankó2004 [15] Hungary 1976-2002 8.46 years 162 PM, DM, JDM, OM, CAM 95 92 89 (10 yr)
Troyanov2005[7] France 1967-2001 8.7 years 100 PM. DM, CAM, OM –– 73(10 yr)
Airio. 2006 [32] Finland 1965-1995 11 years 248
(176PM/
72DM)
PM, DM – 75
(PM)
63
(DM)
55(PM
53(DM)
Torres, et al 2006 [33] Spain 1976-2005 9 years 107 PM, DM, JM, OM, OM,
CAM
92 80 71(10 years)
Yamasaki Y, et al 2011[29] Japan 1984-2010 — 197 PM, DM, ADM, CADM,
OM
85 75 67(10 years)
Ours 2011 China 1986-2010 7.5 years 188 PM, DM, ADM, JM, OM,
CAM
93.6% 88.7 81(10 years), 76.6(15
years)
65.6 (20 years)
Ref, reference; PM, polymyositis; DM, dermatomyositis; CAM, cancer associated myositis; OM, overlap myositis; JM, Juvenile PM/DM.
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Page 9 of 11than that described in others [17,20,41]. Likewise,
patients with JM in our study had no physical disability
at all. Overall, these findings showed marked improve-
ment in functional outcome, disease activity and organ
damage of IIM when compared with earlier literature at
follow-up.
To minimize the bias of data, each data was collected
by one physician, and the collected data was sufficient
for use as a measure of IIM mortality and risk factors.
Our data show that IIM spectrum in this study with
regard to disease onset, clinical symptoms, prevalence of
ILD, malignancy, partial prognostic factors is in general
consistent with previous reports in Japan and European
and American [8-15,20,26-29,35]. But the long-term
outcome was better than previous studies over 15 years
(table 5). These results both supported our data is valid-
ity. We speculated that favorable long-term outcomes of
patients in this study could be attributed to the follow-
ing: (i) positive screening of ILD, cardiac involvement,
PAH, and serologic tests at any time during the clinical
course. (ii) the prevalence of cancer was lower than
others (5.9%). (iii) our patients received earlier adminis-
tration, personalized and combined therapy. (iv)
improvement in patients’ recognition of the disease. (v)
most patients (79.5%) were polycyclic course. (vi) differ-
ences in genetic and environmental backgrounds from
other populations.
However, our study still does have some limitations.
First, this series had a particularly low prevalence of JM
(only seven cases in the whole study), which may have
led to a tendency to overestimate the outcome of JM
patients. Second, we did not obtain details of levels of
muscle enzymes at disease diagnosis from all patients,
which resulted in not analyzing the effects of skeletal
muscle enzymes level on survival, because some patients
were referred to our hospital. However, we still analyzed
whether the serum CK level at initial visit at our center
was associated with prognosis, results found there was
no relation between CK level and prognosis. There is
still some debate on the relationship between CK level
and outcome. It was concluded that the level of CK did
not reach any predictive value for mortality [28,32].
Third, the follow-up time was still relative short. A con-
tinued follow-up of our patients is under way. Another,
organ damage was partly assessed by the MDI using tel-
ephone interview which may have resulted in an under-
estimation of the extent of damage or an inaccurate
reflection of the severity of damage. Further prospective
analyses need to be carried out with face to face inter-
views to examine the organ damage. Finally, we did not
analyze the predicator factors associated with relapse
and relapse frequency which may be beneficial for long-
term outcome. So far, there is no any study about adult
IIM patient reports the predicator factors associated
with relapse and relapse frequency. However, one study
has claimed that the persistence of Gottron’sp a p u l e s
and nailfold abnormalities early in the disease course
was associated with a longer time to remission in juve-
nile dermatomyositis [42]. Future works need to be
done to claim the issues in adult patients with IIM.
Conclusions
In conclusion, despite these limitations, the results of
this study provide strong evidence that patients with
IIM in Chinese Han populations had favorable func-
tional outcomes and less organ damage at long-term fol-
low-up. Those patients most likely to survive had a high
chance of reaching stable disease status, and obtained
long-term or possibly permanent remission to a large
extent.
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